<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04725474</url>
  </required_header>
  <id_info>
    <org_study_id>CTL-002-001</org_study_id>
    <nct_id>NCT04725474</nct_id>
  </id_info>
  <brief_title>First-in-Human Study of the GDF-15 Neutralizing Antibody CTL-002 in Patients With Advanced Cancer (GDFATHER)</brief_title>
  <acronym>GDFATHER</acronym>
  <official_title>A Phase 1, First-in-human (FIH), Two-part, Open-label Clinical Trial of Intravenous (IV) Administration of CTL-002 Given as Monotherapy and/or in Combination With an Anti-PD-1 Checkpoint Inhibitor in Subjects With Advanced-stage, Relapsed/Refractory Solid Tumors, That Relapsed Post or Were Refractory to a Prior Anti-PD-1/PD-L1 Therapy and Have Exhausted All Available Approved Standard Treatments or Are Not Eligible for Them Anymore (the &quot;GDFATHER&quot;-Trial: GDF-15 Antibody-mediaTed Effector Cell Relocation).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CatalYm GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CatalYm GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part A will be a dose escalation study of IV CTL002 (a monoclonal antibody neutralizing&#xD;
      GDF-15) as monotherapy and in combination with an approved checkpoint inhibitor (CPI) in&#xD;
      patients with advanced solid tumors. Part B will be a cohort expansion into up to five solid&#xD;
      tumor indications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be assigned to a dose level of CTL-002 at the time of their enrollment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (Parts A &amp; B)</measure>
    <time_frame>min. 2 months</time_frame>
    <description>Incidence of treatment emergent adverse events in monotherapy and/or combination therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of DLT and MTD (Part A)</measure>
    <time_frame>28 days</time_frame>
    <description>Assessment of toxicities in monotherapy and/or combination therapy per dose level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of clinical efficacy according RECIST (Part B)</measure>
    <time_frame>min. 6 weeks</time_frame>
    <description>RECIST is measured every 6-8 weeks treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax following the first dose of CTL-002 (Part A &amp; B)</measure>
    <time_frame>1 day</time_frame>
    <description>PK parameter from serum CTL-002 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC following the first dose of CTL-002 (Part A &amp; B)</measure>
    <time_frame>14 days</time_frame>
    <description>PK parameter from serum CTL-002 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life of CTL-002 (Part A &amp; B)</measure>
    <time_frame>min. 6 weeks</time_frame>
    <description>PK parameter from serum CTL-002 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of treatment-emergent cytokine/chemokine concentrations (including TNF-a, IFN-g, IL-2, CXCL-9 and CXCL-10) (Part A &amp; B)</measure>
    <time_frame>min. 6 weeks</time_frame>
    <description>Measurement of concentration in peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of clinical efficacy according RECIST (Part A)</measure>
    <time_frame>min. 6 weeks</time_frame>
    <description>RECIST is measured every 6-8 weeks during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of appetite</measure>
    <time_frame>min. 6 weeks</time_frame>
    <description>Assessment of appetite via quality of life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Body-Mass-Index (BMI) (kg/m2)</measure>
    <time_frame>min. 6 weeks</time_frame>
    <description>Calculation of BMI in kg/m2 by combining measurement of body weight in kg and body height in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of lumbar vertebra skeletal muscle index (L3SMI) (cm2/m2)</measure>
    <time_frame>min. 6 weeks</time_frame>
    <description>Combining measurement of L3 vertebra skeletal muscle mass via computed tomography (CT) in cm2 and patient height (squared) in m2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">155</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>Part A: CTL-002 Monotherapy + Checkpoint Inhibitor Combination Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to five dose levels with CTL-002 administered as IV monotherapy and in combination with an checkpoint inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: CTL-002 Monotherapy + Checkpoint Inhibitor combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 2 dose levels with CTL-002 in Part B (expansion)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CTL-002</intervention_name>
    <description>monoclonal antibody</description>
    <arm_group_label>Part A: CTL-002 Monotherapy + Checkpoint Inhibitor Combination Dose Escalation</arm_group_label>
    <arm_group_label>Part B: CTL-002 Monotherapy + Checkpoint Inhibitor combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated informed consent, and able to comply with the study procedures and&#xD;
             any locally required authorization.&#xD;
&#xD;
          -  Male or female aged â‰¥ 18 years.&#xD;
&#xD;
          -  Relapsed/refractory patients with histologically or cytologically confirmed diagnosis&#xD;
             of advanced-stage or recurrent cancer&#xD;
&#xD;
          -  Progressed on/relapsed after at least one prior anti-PD-1/PD-L1 treatment&#xD;
&#xD;
          -  Biopsy-accessible tumor lesions and willing to undergo triple sequential tumor biopsy&#xD;
             (Part A).&#xD;
&#xD;
          -  At least 1 radiologically measurable lesion per RECIST V1.1/imRECIST (Part B).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1.&#xD;
&#xD;
          -  Life expectancy &gt; 3 months as assessed by the Investigator.&#xD;
&#xD;
          -  Adequate organ function (bone marrow, hepatic, renal function and coagulation).&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
&#xD;
          -  Any tumor-directed therapy within 21 days before study treatment.&#xD;
&#xD;
          -  Treatment with investigational agent within 21 days before study treatment.&#xD;
&#xD;
          -  Radiotherapy within 14 days before study treatment.&#xD;
&#xD;
          -  Pre-existing arrhythmia, uncontrolled angina pectoris, uncontrolled heart failure&#xD;
             (NYHA II-IV), any myocardial infarction/coronary event, CNS-ischemic event and any&#xD;
             thromboembolic event at any time &lt; 6 months prior to Screening.&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &lt; 50% measured by echocardiogram or MUGA.&#xD;
&#xD;
          -  QTcF &gt; 450 ms for men or &gt; 470 ms for women.&#xD;
&#xD;
          -  Any active autoimmune requiring systemic immunosuppressive treatments. .&#xD;
&#xD;
          -  Any history of non-infectious pneumonitis &lt; 6 months prior to Screening.&#xD;
&#xD;
          -  Any active inflammatory bowel disease such as Crohn's disease or ulcerative colitis&#xD;
             which are generally excluded or active autoimmunthyroiditis present &lt; 6 months prior&#xD;
             to Screening.&#xD;
&#xD;
          -  History of CNS disease such as stroke, seizure, encephalitis, or multiple sclerosis (&lt;&#xD;
             6 months prior to Screening).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugen Leo, MD, PhD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>CatylYm GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eugen Leo, MD, PhD, MBA / CMO</last_name>
    <phone>+49 89 200066440</phone>
    <email>eugen.leo@catalym.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Petra Fettes, PhD</last_name>
    <phone>+49 89 200066440</phone>
    <email>petra.fettes@catalym.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Essen, Westdeutsches Tumorzentrum, Innere Klinik und Poliklinik</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum WÃ¼rzburg, Comprehensive Cancer Center</name>
      <address>
        <city>WÃ¼rzburg</city>
        <zip>97078</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franziska Goerke</last_name>
      <phone>+49 931 201 409</phone>
      <phone_ext>57</phone_ext>
      <email>Goerke_f@ukw.de</email>
    </contact>
    <contact_backup>
      <last_name>Julia Petzoldt- Weigel</last_name>
      <phone>+49 931 201 409</phone>
      <phone_ext>59</phone_ext>
      <email>Petzoldt_J@ukw.de</email>
    </contact_backup>
    <investigator>
      <last_name>Maria-Elisabeth Goebeler, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ralf Bargou, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cyrus Sayehli, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron, Institute of Oncology</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Garralda, Dr.</last_name>
      <email>egarralda@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Elena Garralda Cabanas, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>START Madrid, Hospital Universitario HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>emiliano.calvo@startmadrid.com</email>
    </contact>
    <investigator>
      <last_name>Emiliano Calvo Aller, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra, Unidad Central de Ensayos Clinicos</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>eecc@unav.es</email>
    </contact>
    <investigator>
      <last_name>Ignacio Melero Bermejo, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich, Department of Dermatology</name>
      <address>
        <city>Zurich</city>
        <zip>9091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reinhard Dummer, Prof. Dr.</last_name>
      <phone>+41 43 253 09 38</phone>
      <email>reinhard.dummer@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Reinhard Dummer, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CTL-002</keyword>
  <keyword>GDF-15</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

